Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...

The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur ...

A new £50 million initiative aims to cut the length of time novel medicines spend in clinical trials, enabling patients to benefit from new treatments much sooner.

The International Drug Development Institute (IDDI) is reinforcing its position as a contract research organization by introducing innovative clinical trial design and analysis solutions that are ...

Expanding clinical trial access locally reduces logistical and financial barriers, making participation feasible for underserved populations. Addressing myths about clinical trials helps patients ...

Clinical trial delays are a pervasive issue in the research industry. In fact, almost 80 percent of trials fail to meet their initial targets and timelines, and 23 percent of participants who enroll ...

When people hear the term “clinical trial,” they often imagine someone with a serious illness, desperate for a last-resort treatment, being poked and prodded in a lab. These images are persistent, but ...